Paz-Gómez FJ

Language: Spanish
References: 38
Page: 13-19
PDF size: 80.59 Kb.

ABSTRACT

The small-round cell tumor (SRCT) family is a diverse group of neoplasms that are primitive or embryonal in appearance and, therefore, haven’t any particular morphologic features that would allow precise identification. This designation is usually reserved for neoplasms of children, adolescents and young adults that involve skeletal system or soft tissue and include members of diverse groups. As consequence of their common morphologic traits, these neoplasms often pose difficult differential diagnostic problems for pathologist and have become a model system for non-morphologic approaches to diagnosis. This review focus on pearls in the diagnostic systems and try to explain to all non-pathologist the complexity in the evaluation of this lesion and the importance to have communication channels with the clinician and a good case approach.

REFERENCES

1. Miettinen M. Small round cell tumor. In Soft tissue tumors. Churchill-Livingston. Philadelphia Pennsylvania. 2003: 427-462.

2. Stocker JT, Mosijcauk AD. Handling of pediatric tumor. Am J Clin Pathol 1998; 109 (Suppl1): S1-S3.

3. Joshi VV. Approach to small round cell tumors of childhood. Pathol Case Rev 2000; 5: 26-41.

4. Landis SH. Cancer statistics 1998. CA Cancer J Clin 1998; 48: 6-29.

5. Handbook of Surgical Oncology. Md. Anderson Cancer Center. Lippincott Williams & Wilkins. 2000. USA.

6. Gerald WL. A practical approach to the differential diagnosis of small round cell tumors of infancy using recent scientific and technical advances. Int J Surg Pathol 2000; 8: 87-97.

7. Barth RJ Jr, Merino MJ, Solomon D, Yang JC, Baker AR. Prospective study of the value of core needles biopsy and fine needle aspiration in the diagnosis of soft tissue masses. Surg 1992; 112: 536-543.

8. Dei Tos AP, Dal Cin P. The role of cytogenetics in the classification of soft tissue tumors. Virchows Arch 1997; 431: 83-94.

9. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991; 67: 1886-1893.

10. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing sarcoma translocation t(21;22), fuses the EWS gene to another ETS-family transcription factor ERG. Nature Genet 1994; 6: 141-155.

11. de Alava E, Ladanyi M, Rosai J, Gerald WL. Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic essay. Am J Pathol 1995; 147: 1584-1591.

12. Stevenson AJ. CD99(p30/32MIC-2) neuroectodermal/Ewing´s sarcoma antigen as an immunohistochemical marker. Review of more than 600 tumors and the literature experience. Appl Immunohistochem Molecul Morphol 1994; 2: 231-240.

13. Halliday BE, Slagel DD, Elsheikh TE, Silverman JF. Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors. Diagn Cytopatol 1998; 19: 410-416.

14. Dei Tos AP. Immunohistochemical demonstration of p30/32MIC2 (CD99) in synovial sarcoma. A potential cause of diagnostic confusion. Appl Immunohistochem 1995; 3: 168-173.

15. Folpe AL, Schmidt RA, Chapman D, Gown AM. Poorly differentiated synovial sarcoma. Immunohistochemical distinction from primitive neuroectodermal tumors and high grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 1998; 22: 673-682.

16. Granter SR, Renshaw AA, Fletcher CD, Bhan AK, Rosenberg AE. CD99 reactivity in mesenchymal chondrosarcoma. Hum Pathol 1996; 27: 1273-1276.

17. Hasegawa SL, Davison JM, Rutten A, Fletcher JA, Fletcher CD. Primary cutaneous Ewing´s sarcoma: Immunophenotypic and molecular cytogenetic evaluation of five cases. Am J Surg Pathol 1998; 2: 310-318.

18. Nicholson SA, McDermott MB, Swanson PE, Wick MR. CD99 and cytokeratin-20 in small cell and basaloid tumors of the skin. Appl Immunohistochem Molecul Morphol 1999; 7: 260-265.

19. Miettinen M, Lehto VP, Badley RA, Virtanen I. Alveolar rhabdomyosarcoma: Demonstration of the muscle type of intermediate filament protein, desmin, as a diagnostic aid. Am J Pathol 1982; 108: 246-251.

20. Miettinen M, Chatten J, Paetau A, Stevenson A. Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 1998; 22: 327-332.

21. Schmidt RA, Cone R, Haas JE, Gown AM. Diagnosis of rhabdomyosarcoma with HHF35, a monoclonal antibody directed against muscle actins. Am J Pathol 1988; 131: 19-28.

22. Tobar A, Avigad S, Zoldan M, Mor C, Goshen Y, Zaizov R. Clinical relevance of molecular diagnosis in childhood rhabdomyosarcoma. Diagn Molecul Pathol 2000; 9: 9-13.

23. Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 1995; 147: 1799-1810.

24. Gu M, Antonescu CR, Guiter G, Huvos AG, Ladanyi M, Zakowski MF. Cytokeratin immunoreactivity in Ewing´sarcoma: Prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol 2000; 24: 410-416.

25. Chan JK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL.Cytokeratin 20 immunoreactivity distinguishes Merkel cell primary cutaneous carcinoma and salivary gland cell carcinomas of various sites. Am J Surg Pathol 1997; 21: 226-234.

26. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, Ambros PF, Sheer D, Turc-Carel C, Triche TJ et al. The Ewing family tumors. A subgroup of small round cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 249-299.

27. Douglas EC. A specific chromosal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 1987; 45: 148-155.

28. Davis RJ, D’Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p35;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-2872.

29. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, Rovera G, Barr FG. Fusion of a fork head domain gene to PAX3 in the solid alveolar rhabdomyosarcoma. Nature Genet 1993; 5: 230-235.

30. Parham DM, Shapiro DN, Downing JR, Webber BL, Douglass EC. Solid alveolar rhabdomyosarcomas with the t(2;13). Report of two cases with diagnostic implications. Am J Surg Pathol 1994; 18: 474-478.

31. Gerald WL. Desmoplastic small round cell tumor: A recently recognized tumor type associated with a unique gene fusion. Adv Anat Pathol 1995; 2: 341-345.

32. De Alava E, Gerald WL. Molecular biology of the Ewing´s sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18: 204-213.

33. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA, Cooper CS. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box of human synovial sarcoma. EMBO J 1995; 14: 2333-2340.

34. Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J, Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol 1995; 147: 1592-1599.

35. Vang R, Biddle DA, Harrison WR, Heck K, Cooley LD. Malignant peripheral nerve sheah tumor with a t(x;18). Arch Pathol Lab Med 2000; 124: 864-867.

36. van de Rijn M, Barr FG, Xiong QB, Hedges M, Shipley J, Fisher C. Poorly differentiated synovial sarcoma. An analysis of clinical, pathologic and molecular genetics features. Am J Surg Pathol 1999; 23: 106-112.

37. O’Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD. Nonspecificity of t(x;16) for the diagnosis of synovial sarcoma. Mod Pathol 2000; 13: 14ª.

38. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA, Cooper CS. Identification of novel genes SYT and SSX involved in the t(x;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502-507.